Efficacy of tocilizumab in patients with severe COVID-19: Survival and clinical outcomes | Zendy

Abeer Albaadani | Zendy; Nazik Eltayeb | Zendy; Eid Alsufyani | Zendy; Salma AlBahrani | Zendy; Shareefah Mohammed Basheri | Zendy; Hawra Albayat | Zendy; Enas Batubara | Zendy; Sulafa Ballool | Zendy; Ayed Al Assiri | Zendy; Fahad Faqihi | Zendy; Ali B. Musa | Zendy; Asirvatham Alwin Robert | Zendy; Nisreen Alsherbeeni | Zendy; Fatehi Elzein | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Efficacy of tocilizumab in patients with severe COVID-19: Survival and clinical outcomes

Author(s) -

Abeer Albaadani,

Nazik Eltayeb,

Eid Alsufyani,

Salma AlBahrani,

Shareefah Mohammed Basheri,

Hawra Albayat,

Enas Batubara,

Sulafa Ballool,

Ayed Al Assiri,

Fahad Faqihi,

Ali B. Musa,

Asirvatham Alwin Robert,

Nisreen Alsherbeeni,

Fatehi Elzein

Publication year - 2021

Publication title -

journal of infection and public health

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.983

H-Index - 35

eISSN - 1876-035X

pISSN - 1876-0341

DOI - 10.1016/j.jiph.2021.05.015

Subject(s) - medicine , tocilizumab , clinical endpoint , covid-19 , mortality rate , disease , clinical trial , infectious disease (medical specialty)

SARS-CoV-2 is associated with a severe inflammatory response contributing to respiratory and systemic manifestations, morbidity, and mortality in patients with coronavirus disease 2019 (COVID-19).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research